Related Experiment Video

Updated: Jun 28, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Medicare Program; revisions to the Medicare Advantage and Prescription Drug Benefit programs. Interim final rule with

    Federal Register
    |November 7, 2008
    PubMed

    Insights

    This rule updates Medicare Advantage (Part C) and prescription drug (Part D) regulations, including new requirements for special needs plans and marketing rules. These changes align with the Medicare Improvements for Patients and Providers Act (MIPPA).

    Area of Science:

    • Health Policy
    • Healthcare Regulation
    • Medicare Program Administration

    Background:

    • The Medicare Advantage (Part C) and Part D programs are undergoing regulatory revisions.
    • Previous regulations required updates to align with new legislative mandates.

    Purpose of the Study:

    • To revise regulations for Medicare Advantage (Part C), Part D, and cost plans.
    • To implement new statutory requirements from the Medicare Improvements for Patients and Providers Act (MIPPA).

    Main Methods:

    • An interim final rule with comment period (IFC) was issued.
    • The IFC introduces conforming changes to existing MA regulations.
    • New requirements for Part C and Part D plan marketing are established.

    Main Results:

    • Revisions address special needs plans (SNP), private-fee-for-service (PFFS), regional PPO (RPPO), and Medicare MSA plans.
    • Updated regulations cover cost-sharing for dual-eligible enrollees.
    • New marketing requirements for Part C and Part D plans are mandated.

    Conclusions:

    • The IFC ensures Medicare regulations reflect recent statutory changes from MIPPA.
    • New marketing rules aim to enhance transparency and compliance for Part C and Part D plans.
    • These updates are effective by November 15, 2008, as stipulated by law.

    Related Concept Videos

    FDA Approved Drugs: Changes to Approved Drugs01:26

    FDA Approved Drugs: Changes to Approved Drugs

    Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
    Drug Products: Biologics, Biosimilars and Interchangeables01:28

    Drug Products: Biologics, Biosimilars and Interchangeables

    Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
    Dosage Regimen: Individualization01:24

    Dosage Regimen: Individualization

    Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

    PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

    Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
    Prescription, Nonprescription and Orphan Drugs01:02

    Prescription, Nonprescription and Orphan Drugs

    Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
    The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...